acta2-optoβ2AR-IRES-lacZ Strain Information Sheet
Common Name: acta2-optoβ2AR-IRES-lacZ
CHROMusTM designation and lines available: R24:B7 Line 5
Jackson Stock number: NA
Development: The rhodopsin based effector, optoβ2AR which on activation generates the second messenger cAMP, was inserted at the ATG site of the acta2 gene in the BAC RP23-370F21 (CHORI) through homologous recombination. The resulting recombinant BAC was injected into the male pronucleus of fertilized oocytes which were then implanted into pseudo pregnant females. Resulting offspring were screened for the presence of the transgene (founders). Colonies were established from each founder and tested for expression.
|# pups born||# founders||# expressers|
Description: The rhodopsin based effector, optoβ2AR is expressed under control of the acta2 promoter, directing expression to smooth muscle cells in blood vessels, airways of the lung and gut. Expression may be present in other smooth muscle containing tissues which have not been examined. An internal ribosome entry site (IRES) allows for co-expression of lacZ as a visual indicator of expression patterns.
Photo-activation of optoβ2AR. Blue light is flashed at t=15 seconds, inducing vasodilation in vascular smooth muscle. See screenshots below.
|Primer B121||ATA GCT CTC AGC AAC CTG TTG GGT|
|Primer B72||TTC AAC ACG GTT TGG AGG CG|
|Expected size of product:||963bp|
94oC 3 minutes
Acknowledgement: Please inform us of any publications resulting from the use of this mouse and use the following statement to acknowledge their development:
“The mouse strain acta2-optoβ2AR-IRES-lacZ was developed by CHROMusTM; funded by NIH R24HL120847.”